Advanced Age Impairs Cardioprotective Function of Mesenchymal Stem Cell Transplantation from Patients to Myocardially Infarcted Rats
Authors:
- Tao LiuTLTao Liu
- Jinsong HanJHJinsong Han
- Zhonglu YangZYZhonglu Yang
- Xiaodong XueXXXiaodong Xue
- Hui JiangHJHui Jiang
- Huishan WangHWHuishan Wang
Open Access
- 1 May 2014
- journal article
- Published by S. Karger AG in Cardiology
- Vol. 128 (2) , 209-219
Abstract
Objectives: Mesenchymal stem cells (MSCs) have limited clinical therapeutic effects in older myocardial infarction (MI) patients. Thus, whether younger MSCs might confer greater protection is worth investigating. Methods: Human MSCs (hMSCs) were isolated before coronary artery bypass graft surgery and growth characteristics of hMSCs at passage 3 were observed. Vascular endothelial growth factor (VEGF) and Bcl-2 mRNA and protein expression from hMSCs were measured. In vivo, 45 adult male rats with MI were randomized to receive one of three treatments: old hMSCs, young hMSCs or culture medium (control) transplanted into infarcted myocardium. Echocardiography, TUNEL, immunohistochemistry and Western blot were used to assess results. Results: hMSC proliferation in the old group was significantly lower than the young group. VEGF decreased 35% and Bcl-2 decreased more than 60% at the mRNA level; VEGF and Bcl-2 protein were decreased in the old versus the young group. hMSC transplantation may improve cardiac function, but MSC source may affect therapeutic efficacy. Similar data were obtained from TUNEL, immunohistochemistry and Western blot. Conclusion: Transplantation of hMSCs improves heart function, but proliferative ability and myocardial protection decrease with older MSCs, likely due to differences between VEGF and Bcl-2 expression and reduced anti-apoptosis.Keywords
This publication has 41 references indexed in Scilit:
- Impaired cardioprotective function of transplantation of mesenchymal stem cells from patients with diabetes mellitus to rats with experimentally induced myocardial infarctionCardiovascular Diabetology, 2013
- Cyclosporin variably and inconsistently reduces infarct size in experimental models of reperfused myocardial infarction: a systematic review and meta‐analysisBritish Journal of Pharmacology, 2011
- Increased expression of pigment epithelium-derived factor in aged mesenchymal stem cells impairs their therapeutic efficacy for attenuating myocardial infarction injury‡European Heart Journal, 2011
- VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferationJournal of Cardiothoracic Surgery, 2011
- The Effect of Age on the Efficacy of Human Mesenchymal Stem Cell Transplantation after a Myocardial InfarctionRejuvenation Research, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJACC, 2009
- Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacityProceedings of the National Academy of Sciences, 2009
- Paracrine Mechanisms in Adult Stem Cell Signaling and TherapyCirculation Research, 2008
- Aging and Disease as Modifiers of Efficacy of Cell TherapyCirculation Research, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006